Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07221513

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension (RENEU-PH)

A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)

Sponsor: Salubris Biotherapeutics Inc

Conditions Group 2 Pulmonary Hypertension HFpEF - Heart Failure With Preserved Ejection Fraction HFrEF - Heart Failure With Reduced Ejection Fraction

Interventions JK07

Updated 2 times since 2025 Last updated: Jan 16, 2026 Started: Dec 15, 2025 Primary completion: Sep 30, 2026 Completion: Oct 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Group 2 Pulmonary Hypertension and HFpEF - Heart Failure With Preserved Ejection Fraction and is currently actively recruiting participants. Salubris Biotherapeutics Inc leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Nov 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Salubris Biotherapeutics Inc

Data source: Salubris Biotherapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tulsa, United States